A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C

Summary

This 2-part, randomized, double-blind, placebo-controlled study will assess the safety, pharmacokinetics and pharmacodynamics of RO5428029 in healthy volunteers and patients with hepatitis C infection. Cohorts will be randomized to receive either RO5428029 in ascending doses or placebo for up to 7 days (patients) or up to 14 days (healthy volunteers).

Timeline

Start

2011-06

Primary completion

2011-12

Completion

2011-12

Drugs

Indications